These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32486191)

  • 1. Rapid Clathrin-Mediated Uptake of Recombinant α-Gal-A to Lysosome Activates Autophagy.
    Ivanova MM; Dao J; Kasaci N; Adewale B; Fikry J; Goker-Alpan O
    Biomolecules; 2020 May; 10(6):. PubMed ID: 32486191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mannose 6-phosphate receptor and sortilin mediated endocytosis of α-galactosidase A in kidney endothelial cells.
    Prabakaran T; Nielsen R; Satchell SC; Mathieson PW; Feldt-Rasmussen U; Sørensen SS; Christensen EI
    PLoS One; 2012; 7(6):e39975. PubMed ID: 22768187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease.
    Porto C; Pisani A; Rosa M; Acampora E; Avolio V; Tuzzi MR; Visciano B; Gagliardo C; Materazzi S; la Marca G; Andria G; Parenti G
    J Inherit Metab Dis; 2012 May; 35(3):513-20. PubMed ID: 22187137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease.
    Marchesan D; Cox TM; Deegan PB
    J Inherit Metab Dis; 2012 Nov; 35(6):1107-17. PubMed ID: 22450713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
    Choi JO; Lee MH; Park HY; Jung SC
    J Biomed Sci; 2010 Apr; 17(1):26. PubMed ID: 20398385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.
    Zhu X; Yin L; Theisen M; Zhuo J; Siddiqui S; Levy B; Presnyak V; Frassetto A; Milton J; Salerno T; Benenato KE; Milano J; Lynn A; Sabnis S; Burke K; Besin G; Lukacs CM; Guey LT; Finn PF; Martini PGV
    Am J Hum Genet; 2019 Apr; 104(4):625-637. PubMed ID: 30879639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.
    Hsu J; Serrano D; Bhowmick T; Kumar K; Shen Y; Kuo YC; Garnacho C; Muro S
    J Control Release; 2011 Feb; 149(3):323-31. PubMed ID: 21047542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion.
    Condori J; Acosta W; Ayala J; Katta V; Flory A; Martin R; Radin J; Cramer CL; Radin DN
    Mol Genet Metab; 2016 Feb; 117(2):199-209. PubMed ID: 26766614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice.
    Shen JS; Busch A; Day TS; Meng XL; Yu CI; Dabrowska-Schlepp P; Fode B; Niederkrüger H; Forni S; Chen S; Schiffmann R; Frischmuth T; Schaaf A
    J Inherit Metab Dis; 2016 Mar; 39(2):293-303. PubMed ID: 26310963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
    Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
    Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
    Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice.
    Christensen EI; Zhou Q; Sørensen SS; Rasmussen AK; Jacobsen C; Feldt-Rasmussen U; Nielsen R
    J Am Soc Nephrol; 2007 Mar; 18(3):698-706. PubMed ID: 17287429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry mice.
    Pagant S; Huston MW; Moreira L; Gan L; St Martin S; Sproul S; Holmes MC; Meyer K; Wechsler T; Desnick RJ; Yasuda M
    Mol Ther; 2021 Nov; 29(11):3230-3242. PubMed ID: 33775910
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Kytidou K; Beekwilder J; Artola M; van Meel E; Wilbers RHP; Moolenaar GF; Goosen N; Ferraz MJ; Katzy R; Voskamp P; Florea BI; Hokke CH; Overkleeft HS; Schots A; Bosch D; Pannu N; Aerts JMFG
    J Biol Chem; 2018 Jun; 293(26):10042-10058. PubMed ID: 29674318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice.
    Higuchi K; Yoshimitsu M; Fan X; Guo X; Rasaiah VI; Yen J; Tei C; Takenaka T; Medin JA
    Mol Med; 2010; 16(5-6):216-21. PubMed ID: 20454522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Galactosidase delivery using 30Kc19-human serum albumin nanoparticles for effective treatment of Fabry disease.
    Lee HJ; Park HH; Sohn Y; Ryu J; Park JH; Rhee WJ; Park TH
    Appl Microbiol Biotechnol; 2016 Dec; 100(24):10395-10402. PubMed ID: 27353764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.
    Macedo MF; Quinta R; Pereira CS; Sa Miranda MC
    Mol Genet Metab; 2012 May; 106(1):83-91. PubMed ID: 22425450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases.
    Ivanova MM; Changsila E; Iaonou C; Goker-Alpan O
    PLoS One; 2019; 14(1):e0210617. PubMed ID: 30633777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracerebroventricular enzyme replacement therapy with β-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice.
    Chen JC; Luu AR; Wise N; Angelis R; Agrawal V; Mangini L; Vincelette J; Handyside B; Sterling H; Lo MJ; Wong H; Galicia N; Pacheco G; Van Vleet J; Giaramita A; Fong S; Roy SM; Hague C; Lawrence R; Bullens S; Christianson TM; d'Azzo A; Crawford BE; Bunting S; LeBowitz JH; Yogalingam G
    J Biol Chem; 2020 Sep; 295(39):13532-13555. PubMed ID: 31481471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
    Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA
    Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.